###begin article-title 0
Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: Interim results of a prospective cohort study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
We sought to examine the detection rate of cancer cells in peripheral blood (PBL) and in bone marrow (BM) using an established 7-gene marker panel and evaluated whether there were any definable associations of any individual gene with traditional predictors of prognosis.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with T1-T3 primary breast cancer were enrolled into a prospective, multi-institutional cohort study. In this interim analysis 215 PBL and 177 BM samples were analyzed by multimarker, real-time RT-PCR analysis designed to detect circulating and disseminated breast cancer cells.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 362 365 362 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam</italic>
At a threshold of three standard deviations from the mean expression level of normal controls, 63% (136/215) of PBL and 11% (19/177) of BM samples were positive for at least one cancer-associated marker. Marker positivity in PBL demonstrated a statistically significant association with grade II-III (vs. grade I; p = 0.0083). Overexpression of the mammaglobin (mam) gene alone had a statistically significant association with high tumor grade (p = 0.0315), and showed a trend towards ER-negative tumors and a high risk category. There was no association between marker positivity in PBL and the pathologic (H&E) and/or molecular (RT-PCR) status of the axillary lymph nodes (ALN).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
This study suggests that molecular detection of circulating cancer cells in PBL detected by RT-PCR is associated with high tumor grade and specifically that overexpression of the mam gene in PBL may be a poor prognostic indicator. There was no statistically significant association between overexpression of cancer-associated genes in PBL and ALN status, supporting the concept of two potentially separate metastatic pathways.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 640 641 640 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 741 744 741 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam</italic>
###xml 766 770 766 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19</italic>
###xml 942 948 942 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM </italic>
###xml 1017 1019 1017 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
There is a significant amount of ongoing work aimed at defining the role of circulating tumor cells (CTC) in peripheral blood (PBL) and disseminated tumor cells (DTC) in bone marrow (BM) of breast cancer patients. However, due to a variety of available tumor cell detection methods and use of different gene-markers, recently published studies show a wide range of results that are often contradictory and difficult to compare to one another. The main tumor cell detection methods have been immunocytochemistry (ICC) with cytokeratin-specific antibodies [1-11] and RT-PCR analysis based on overexpression of cancer-associated gene-markers [4,6,12-29]. PCR methodology for detection of breast cancer has most frequently employed mammaglobin (mam) and cytokeratin 19 (CK19) genes. Some studies have also used a new CellSearch System technology that employs immunomagnetic separation of epithelial cells based upon expression of cytokeratins or EpCAM and visualization of the tumor cells by immunoflorescent microscopy [30].
###end p 11
###begin p 12
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 558 566 <span type="species:ncbi:9606">patients</span>
Our laboratory has extensive experience in detection of cancer cells using multi-marker real-time RT-PCR methodology [31-35]. To address the clinical relevance of molecular detection of occult breast cancer, we initiated a multi-institutional prospective cohort study. The primary objective of the study was to determine whether the molecular detection of occult breast cancer by multi-marker real-time RT-PCR in patients with pathology-negative axillary lymph nodes (ALN) is a clinically relevant predictor of disease recurrence. An interim analysis of 489 patients enrolled in the study showed a statistically significant association between molecular detection of occult breast cancer in the ALN and traditional predictors of poor prognosis in subjects with pathology-negative ALN [33]. In addition, in a separate publication we show that the sensitivity of sentinel lymph node (SLN) analysis to predict pathologic status of ALN was significantly increased by the addition of molecular analysis [34].
###end p 12
###begin p 13
###xml 456 464 <span type="species:ncbi:9606">patients</span>
###xml 494 502 <span type="species:ncbi:9606">patients</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
There are several cancer-associated gene markers used in the detection of breast cancer cells. Based on the heterogenous nature of the breast cancer, the multi-marker panel approach has shown to increase the sensitivity of molecular assay to detect the presence of disseminated cancer cells. However, the prognostic value of each individual marker is not known and therefore the ultimate goal would be to identify genes that are capable of differentiating patients with poor prognosis from the patients with a more favorable prognosis. Having a tool to recognize the subset of patients with unfavorable molecular characteristics could potentially translate into a better clinical outcome. In this interim analysis we examine the detection rate of cancer cells in PBL and in BM using an established 7-gene marker panel and evaluated whether there were any definable associations of any individual gene with the traditional predictors of prognosis.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
MIMS Trial Study Design
###end title 15
###begin p 16
###xml 985 987 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 80 92 <span type="species:ncbi:9606">participants</span>
###xml 469 474 <span type="species:ncbi:9606">human</span>
###xml 594 599 <span type="species:ncbi:9606">Human</span>
###xml 893 901 <span type="species:ncbi:9606">patients</span>
###xml 1037 1045 <span type="species:ncbi:9606">patients</span>
###xml 1085 1093 <span type="species:ncbi:9606">patients</span>
A prospective cohort study design was adopted where, upon recruitment, eligible participants with Stage I, IIa, or IIb breast cancer were requested to consent to tissue sampling from axillary lymph nodes (ALN), sentinel nodes (SLN), bone marrow (BM), and peripheral blood (PBL). Tissue sampling was accomplished at the time of surgical intervention. The study was carried out in compliance with the Helsinki Declaration ethical principles in medical research involving human subjects. All specimens were collected through the Medical University of South Carolina Institutional Review Board for Human Research approved protocols (HR 9551, HR 8374, HR 8903, HR 8432). Informed consent was obtained in accordance with each participating center's Institutional Review Board guidelines. The design, enrollment criteria, tissue acquisition protocols, and determination of gene expression values for patients enrolled in the MIMS trial are described in more detail in a separate publication [33]. The current study focuses on the subset of 215 patients with PBL samples and the subset of 177 patients with BM samples. Real-time RT-PCR analyses for cancer-associated genes were performed on all specimens at the Central Molecular Diagnostics Laboratory at the Medical University of South Carolina (MUSC). The Clinical Innovation Group (TCIG, Charleston, SC) (later known as the Data Coordination Unit (DCU) in the Department of Biostatistics, Bioinformatics and Epidemiology at MUSC) served as the coordinating center, and all study data were collected, processed and analyzed at this central facility.
###end p 16
###begin title 17
Blood and bone marrow samples from breast cancer subjects
###end title 17
###begin p 18
###xml 41 48 <span type="species:ncbi:9606">patient</span>
###xml 1211 1219 <span type="species:ncbi:9606">patients</span>
Bone marrow aspirates were obtained from patient's left and or right anterior or posterior iliac crests under anesthesia at the time of operation. A 10 or 20 cc syringe with a 16-18 gauge bone marrow aspirate needle was used to aspirate 3-6 ml of bone marrow into a syringe and then immediately transferred to a sterile EDTA vacutainer. Peripheral blood samples were obtained before surgery or following the induction of anesthesia. A total of 5-10 ml of blood was drawn from a peripheral vein into a sterile EDTA vacutainer. Blood and bone marrow samples were then shipped at room temperature to the Central Molecular Diagnostics Laboratory at the MUSC for immediate processing by Ficoll density gradient centrifugation (Ficoll-Paque Plus; Amersham Biosciences). All the specimens inside US arrived in 24 hours and international shipments arrived in 48 hours. One mL of bone marrow was used for Cytospin preparation and stained for ICC analysis. These bone marrow samples were evaluated by a cytopathologist for the presence of micrometastases using cytokeratin AE1/AE3. Please note that the specimen acquisition protocol was amended after the initiation of the MIMS trial and for that reason only a subset of patients was included in this analysis.
###end p 18
###begin title 19
Blood and bone marrow samples from control subjects without evidence of malignancy
###end title 19
###begin p 20
###xml 204 212 <span type="species:ncbi:9606">patients</span>
In order to define baseline expression levels for the molecular markers used in this study, PBL and BM samples from control subjects were procured. Informed consent was obtained for BM aspiration from 49 patients undergoing orthopedic surgery at MUSC and for PBL drawn from 49 healthy volunteers. None of the control subjects had any history or clinical evidence of malignancy. Four to six ml of BM aspirate or 5-10 ml of PBL was transferred to an EDTA vacutainer and sent to the Central Molecular Diagnostics Laboratory to be processed by Ficoll density gradient centrifugation and analyzed by real-time RT-PCR.
###end p 20
###begin title 21
RNA isolation and cDNA synthesis
###end title 21
###begin p 22
###xml 834 840 812 818 <sub xmlns:xlink="http://www.w3.org/1999/xlink">12&#8211;16 </sub>
Buffy coats were obtained by Ficoll density gradient centrifugation, and total cellular RNA was isolated using a guanidinium thiocyanate-phenol-chloroform solution (RNA STAT-60trade mark; TEL-TEST, Friendswood, TX). Briefly, cells were re-suspended in 1 ml of RNA STAT-60trade mark. Total RNA was isolated as per the manufacturer's instructions with the exception that 1 muL of a 50 mg/mL solution of glycogen (Sigma, St. Louis, MO) was added to the aqueous phase prior to addition of isopropanol. Glycogen was used as a nucleic acid carrier to enhance RNA precipitation. The RNA pellet was dissolved in 50 mul of 1x RNA secure buffer (Ambion, Austin, TX). RNA was quantified by spectrophotometry at 260 nm. cDNA was made from 5 mug of total RNA using 200 U of M-MLV reverse transcriptase (Promega, Madison, WI) and 0.5 mug Oligo (dT)12-16 in a reaction volume of 20 mul (10 min at 70degreesC, 50 min at 42degreesC, 15 min at 70degreesC).
###end p 22
###begin title 23
Real-time RT-PCR
###end title 23
###begin p 24
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 71 77 71 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mglo: </italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PDEF: </italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam: </italic>
###xml 258 264 258 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19: </italic>
###xml 321 327 321 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1: </italic>
###xml 383 388 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP: </italic>
###xml 445 452 445 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM: </italic>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2</italic>
###xml 621 625 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 825 826 822 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 901 904 898 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 920 924 915 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1067 1071 1053 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1382 1383 1342 1343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t</sub>
The real-time RT-PCR primers have been previously reported [31,36,37]: mglo: F 5'-GCCGTGTGAACCATGTGACTTT, R 5'-CCAAATGCGGCATCTTCAAA; PDEF: F 5'-AGTGCTCAAGGACATCGAGACG, R 5'-AGCCACTTCTGCACATTGCTG; mam: F 5'-CGGATGAAACTCTGAGCAATGT, R 5'-CTGCAGTTCTGTGAGCCAAAG; CK19: F 5'-CATGAAAGCTGCCTTGGAAGA, R 5'-TGATTCTGCCGCTCACTATCAG; muc1: F 5'-ACCATCCTATGAGCGAGTACC, R 5'-ACCATCCTATGAGCGAGTACC; PIP: F 5'-GCCAACAAAGCTCAGGACAAC, R 5'-GCAGTGACTTCGTCATTTGGAC; EpCAM: F 5'-CGCAGCTCAGGAAGAATGTG, R 5'-TGAAGTACACTGGCATTGACGA; ErbB2: F 5'-CTGGTGACACAGCTTATGCCCT, R 5'-ATCCCCTTGGCAATCTGCA. Analyses were performed on a PE Biosystems Gene Amp(R) 5700 Sequence Detection System (Foster City, CA). All reaction components were purchased from PE Biosystems. The standard reaction volume was 10 mul and contained 1X SYBR Green PCR Buffer; 3.5 mM MgCl2; 0.2 mM each of dATP, dCTP, and dGTP; 0.4 mM of dUTP; 0.25 U AmpliTaq Gold(R); 0.1 U AmpErase(R) UNG enzyme; 0.7 mul cDNA template; and 0.25 mM of both forward and reverse primer. The initial step of PCR was 2 min at 50degreesC for AmpErase(R) UNG activation, followed by a 10-min hold at 95degreesC. Cycles (n = 40) consisted of a 15 sec denaturation step at 95degreesC, followed by a 1 min annealing/extension step at 60degreesC. The final step was a 60degreesC incubation for 1 min. All reactions were performed in triplicate. The cycle of threshold (Ct) analysis was set at 0.5 relative fluorescence units.
###end p 24
###begin title 25
Primary data analysis
###end title 25
###begin p 26
###xml 42 44 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 120 122 120 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 188 190 188 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 345 362 345 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;2-microglobin</italic>
###xml 389 391 386 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 400 418 397 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;2-microglobin </italic>
###xml 433 435 427 429 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 472 474 462 464 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 501 503 491 493 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 514 518 504 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;</italic>
###xml 518 519 505 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 519 532 506 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-microglobin </italic>
###xml 737 739 724 726 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1236 1238 1219 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 1009 1017 <span type="species:ncbi:9606">patients</span>
###xml 1611 1619 <span type="species:ncbi:9606">patients</span>
Real-time RT-PCR data were quantified as Ct values that are inversely related to the amount of starting template: high Ct values correlate with low levels of gene expression, whereas low Ct values correlate with high levels of gene expression. Each gene was analyzed in triplicate. Results were normalized to an internal control reference gene, beta2-microglobin, by subtracting the mean Ct value of beta2-microglobin from the mean Ct value of each respective gene (DeltaCt value). Samples for which Ct values for beta2-microglobin were equal or higher than 22 were considered to contain inadequate RNA and were excluded from the analysis. Approximately 10% of samples we rejected from the analysis based on this criterion. If the mean Ct value for a gene of interest was higher or equal to 38, the gene expression was considered to be undetectable. In order to define baseline levels of gene expression and to define thresholds for marker positivity, 49 specimens of PBL and 49 specimens of BM obtained from patients with no evidence of malignancy were analyzed. To be consistent with the previous molecular analyses of lymph nodes, threshold values for each individual marker were set at three standard deviations from the mean DeltaCt value in the control group. A subject was considered to be positive for the molecular analysis if at least one marker in the panel was above the defined threshold. Data from real-time RT-PCR analyses were compiled in a Microsoft Access database and submitted to the DCU at MUSC for statistical analyses. The molecular analysis was generated blinded to clinical outcome and patients' clinicopathologic data.
###end p 26
###begin title 27
Bone marrow cytopathology and cytokeratin ICC staining
###end title 27
###begin p 28
###xml 43 47 43 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 101 105 99 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 616 618 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 887 888 883 884 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 889 891 885 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 925 926 921 922 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Specimens were collected, washed in CytoLyt(R) (Cytyc, Boston, MA) and then resuspended in PreservCyt(R) (Cytyc). Two ThinPrep (TP) slides were prepared and stained with Papanicolaou stain, and one slide was used for immunocytochemistry (ICC). A monoclonal antibody for cytokeratin (AE1/AE3) was used in conjunction with an automated immunostaining system (DAKO Autostainer, DAKO Cytomation, Carpeteria, CA) and a Nexus immunohistochemistry slide staining apparatus (Ventana Medical Systems Inc, Tuscon, AZ). Immunostaining was performed with the avidin-biotin immunoperoxidase (ABC-peroxidase) method of Hsu et al [38]. Briefly, the slides were incubated with primary antibody for 30 minutes and then incubated with secondary biotinylated antibody for 4 minutes. To visualize the antibody, the TP was treated with diaminobenzidine (0.05%) in 0.05 M Tris-HCL buffer (pH 7.8) with 0.03% H2O2 for 6 minutes and then washed in H2O. TP was counterstained with hematoxylin, dehydrated, cleared in xylene, and mounted in Permount. The specimens were analyzed by a skilled cytopathologist.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 545 561 545 561 <underline xmlns:xlink="http://www.w3.org/1999/xlink">minimal/low risk</underline>
###xml 638 655 634 651 <underline xmlns:xlink="http://www.w3.org/1999/xlink">intermediate risk</underline>
###xml 727 736 723 732 <underline xmlns:xlink="http://www.w3.org/1999/xlink">high risk</underline>
###xml 838 840 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
SAS Version 9.1 Software (SAS Institute Inc., SAS Campus Drive, Cary, North Carolina) was used for the analysis of pathological and molecular outcome. Chi-square analyses were conducted to explore the association between pre-defined baseline covariates that have been associated with pathological outcome in prior studies and PBL and BM RT-PCR positivity/negativity status. Pre-defined baseline covariates were tumor size, histological grade, estrogen receptor status, progesterone receptor status, her2neu status, and St. Gallen risk category (minimal/low risk: tumor size </= 1 cm, positive ER and/or PR status, grade I and age >/= 35; intermediate risk: tumor size >1 or 2 cm, positive ER and/or PR status, and grade I; and high risk: lymph node positive, tumor size > 2 cm, negative ER and/or PR status, grade II or III, or age <35) [39]. Statistical significance was defined as p-values < 0.05.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
Demographic and clinicopathologic analysis
###end title 32
###begin p 33
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
The distribution of the demographic and clinicopathologic characteristics in Table 1 indicate that the subset of patients with PBL analysis (n = 215) and the subset of patients with BM analysis (n = 177) are representative of the entire study group of 489 [33].
###end p 33
###begin p 34
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Demographic and Clinicopathologic Characteristics
###end p 34
###begin title 35
Precise quantitation of gene-marker expression in normal control bone marrow and peripheral blood samples
###end title 35
###begin p 36
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 214 250 214 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam, CEA, CK19, PIP, muc1, PSE, Erb </italic>
###xml 264 270 264 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM </italic>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 526 528 526 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 742 744 734 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 851 855 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19</italic>
###xml 857 862 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1 </italic>
###xml 866 872 858 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2 </italic>
We have previously shown that the majority of known breast cancer-associated genes have some background expression in normal lymph nodes [31,36,37]. For this study we selected seven breast cancer-associated genes [mam, CEA, CK19, PIP, muc1, PSE, Erb (BM only) and EpCAM (PBL only)] known to be over-expressed in metastatic breast cancer compared to control lymph nodes [31,36,37]. For this study, baseline gene expression was precisely quantitated in 49 normal PBL samples and 49 normal BM samples by real-time RT-PCR (Figure 1A and 1B; horizontal lines indicate the DeltaCt thresholds). To obtain maximum specificity, a threshold value for marker positivity, i.e. abnormal expression was set at three standard deviations from the mean DeltaCt value for each gene. Out of seven cancer-associated gene-markers used to detect tumor cells in PBL and BM, CK19, muc1 and ErbB2 were not informative due to the high expression in normal control samples.
###end p 36
###begin p 37
###xml 0 220 0 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Real-time RT-PCR analysis of cancer-associated gene expression in peripheral blood (A) and bone marrow (B) from breast cancer patients (filled triangle) and in normal control blood and bone marrow samples (empty circles)</bold>
###xml 228 230 224 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 276 278 272 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 320 322 313 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 354 356 347 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
###xml 580 584 565 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 591 595 576 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 602 606 587 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEA </italic>
###xml 613 617 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE </italic>
###xml 624 629 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 635 644 620 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1 7.57</italic>
###xml 646 652 631 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM </italic>
###xml 672 676 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 683 687 668 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 694 698 679 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEA </italic>
###xml 705 709 690 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE </italic>
###xml 716 721 701 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 727 732 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1 </italic>
###xml 738 744 723 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2 </italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Real-time RT-PCR analysis of cancer-associated gene expression in peripheral blood (A) and bone marrow (B) from breast cancer patients (filled triangle) and in normal control blood and bone marrow samples (empty circles). DeltaCt values were obtained by subtracting the mean Ct value of beta2-microglobin from the mean Ct value of each respective gene. Ct values for each gene were determined from triplicate reactions. Horizontal lines indicate DeltaCt threshold values (3 standard deviations from the mean). The DeltaCt threshold for each gene are as follows: Peripheral blood: mam 24.00, PIP 24.19, CEA 21.93, PSE 15.28, CK19 6.32, muc1 7.57, EpCAM 15.49; Bone marrow: mam 22.00, PIP 18.32, CEA 12.64, PSE 12.48, CK19 0.20, muc1 3.41, ErbB2 1.77.
###end p 37
###begin title 38
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Real-time RT-PCR analysis of gene expression in peripheral blood of breast cancer patients
###end title 38
###begin p 39
###xml 34 53 34 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam, PIP, CEA, PSE </italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM</italic>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE </italic>
###xml 365 369 365 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEA </italic>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 418 422 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 442 448 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM </italic>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 773 777 773 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE </italic>
###xml 985 986 985 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1016 1020 1016 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 1200 1201 1200 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 622 630 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 706 714 <span type="species:ncbi:9606">patients</span>
Using the five-marker gene-panel (mam, PIP, CEA, PSE and EpCAM) at the threshold of three standard deviations above the mean expression level in normal control samples for each gene, 136 (63%) patients out of 215 were positive for at least one marker. On an individual marker basis (Table 2), the most frequently over-expressed markers were PSE (58/215; 27.0%) and CEA (51/215; 23.7%) followed by PIP (36/215; 16.7%), mam (29/215; 13.5%) and EpCAM (7/215; 3.3%). Marker positivity in PBL demonstrated a statistically significant association with grade II-III (vs. grade I; p = 0.0083; Table 3). Out of 136 RT-PCR positive patients 97 patients (71%) were positive for one, 33 patients (24%) for two and six patients (4%) for three markers. Interestingly, over-expression of PSE gene had statistically significant association with ER-positive and PR-positive tumors (p = 0.0123 and p = 0.0134, respectively) and showed a trend towards pathology-negative nodal status (31% vs. 19%; Table 3). However, overexpression of mam gene had statistically significant association with high grade (p = 0.0315) and showed a trend towards ER-negative tumors (22% vs. 11%) and a high risk category (15% vs. 6%; Table 3). Interestingly, there was no association between marker positivity in PBL and either pathologic (H&E) status or molecular (multi-marker qRT-PCR) status of axillary lymph nodes.
###end p 39
###begin p 40
Positivity of cancer-associated genes in peripheral blood and bone marrow specimens
###end p 40
###begin p 41
###xml 8 10 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
* DeltaCt threshold was set 3 standard deviations from the mean in normal samples
###end p 41
###begin p 42
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Association of molecular positivity in peripheral blood of breast cancer patients with traditional predictors of prognosis.
###end p 42
###begin p 43
P-values obtained by Chi-square analysis or *Fisher's exact test
###end p 43
###begin title 44
Real-time RT-PCR analysis of cancer-associated gene expression in bone marrow
###end title 44
###begin p 45
###xml 32 45 32 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam, PIP, CEA</italic>
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE</italic>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 486 490 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 535 539 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE </italic>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CEA </italic>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
Using a four-marker gene-panel (mam, PIP, CEA, and PSE) at the threshold of three standard deviations above the mean expression level in normal control samples for each gene, 19 patients (11%) out of 177 were positive. All 19 were positive to one marker only. Marker positivity in bone marrow had no statistically significant association with any of the traditional prognostic indicators. Looking at individual markers separately (Table 2), the most frequently overexpressed marker was mam (7/177; 4.0%) followed by PIP (5/177; 2.8%), PSE (5/177; 2.8%) and CEA (2/177; 1.1%)
###end p 45
###begin title 46
Comparison of molecular analysis of blood and bone marrow
###end title 46
###begin p 47
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 360 364 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 438 442 438 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 446 450 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
To determine whether there was an association between molecular analysis in PBL and molecular analysis in BM, we performed Chi-Square and Fisher's Exact test on 138 patients that had results from both PBL and from BM (Table 4). Comparison of the results using gene-panel data did not show statistically significant association, however, the results of mam and PIP gene expression in PBL had statistically significant association with the mam and PIP gene expression in BM (p = 2.5E-04 and p = 0.0188, respectively).
###end p 47
###begin p 48
Comparison between molecular analysis of peripheral blood (PBL) and molecular analysis of bone marrow (BM).
###end p 48
###begin p 49
P-values obtained by Chi-square analysis or *Fisher's exact test
###end p 49
###begin title 50
Immunocytochemistry (ICC) versus RT-PCR in bone marrow
###end title 50
###begin p 51
###xml 295 299 295 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 313 316 313 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP</italic>
###xml 414 415 414 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
BM cytopathology assessment resulted in detection of no abnormal or suspicious cells. Eighty three BM samples were randomly selected for additional cytokeratin ICC staining. Five out of 83 (6%) samples were positive by ICC and two of these samples were also positive by RT-PCR (one positive for mam and other for PIP). Ten patients out of 83 (12%) that had inconclusive ICC results were all RT-PCR negative (Table 5). Although there was 84% agreement (excluding inconclusive ICC results) between 2 methodologies, this was mostly because of the concordance of dual negative findings. Overall there was no statistically significant association between ICC and PCR data (Chi-Square 0.1064; Fisher's exact test 0.1607; ICC inconclusive results excluded).
###end p 51
###begin p 52
Comparison between immunocytochemistry (ICC) and RT-PCR analysis in bone marrow.
###end p 52
###begin p 53
*P-value obtained by Fisher's exact test
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 520 556 520 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam, CEA, CK19, PIP, muc1, PSE, Erb </italic>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM </italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
This paper describes molecular analyses of PBL and BM samples from a subgroup of breast cancer patients who were enrolled into a prospective multi-institutional study with the primary goal to establish the clinical relevance of micrometastatic disease detected by RT-PCR in pathology negative axillary lymph nodes. Our previous reports from this study strongly suggest that over-expression of cancer-associated gene-marker is a valid surrogate for occult micrometastatic breast cancer [33,34]. Using these gene markers [mam, CEA, CK19, PIP, muc1, PSE, Erb (BM only) and EpCAM (PBL only)] we analyzed 215 PBL samples and 177 BM samples from patients with T1-T3 primary breast cancer without clinical evidence of metastatic disease.
###end p 55
###begin p 56
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 496 499 496 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam</italic>
###xml 545 550 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 662 667 662 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 719 724 719 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1078 1082 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19</italic>
###xml 1084 1088 1084 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">muc1</italic>
###xml 1090 1094 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSE </italic>
###xml 1098 1104 1098 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EpCAM </italic>
###xml 1561 1563 1561 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
Using a predetermined rigorous threshold level (three standard deviations from the mean expression in normal PBL), 136 patients out of 215 (63.3%) had a positive signal in at least one cancer-associated marker in their PBL sample. According to the other studies, the incidence of CTC in PBL detected by RT-PCR ranged from 5% to 62% for one-marker analyses [13,15,16,19-24,26-29] and from 31% to 83% for analyses by multi-marker gene-panels [25-29]. The most frequently used markers were CK19 and mam. Our study, in contradiction, suggested that CK19 has high expression level in normal control samples and is therefore not reliable detector of CTC. Although the CK19 primers were designed to avoid the amplification of CK19 pseudogenes [40], we recognize that we cannot entirely exclude this possibility. In addition, we are aware of the limitations of using Ficoll density gradient cell separation methodology. Because of the low tumor cell burden in PBL and BM, the accuracy of tumor cell detection is greatly affected by the gene background expression levels. The genes like CK19, muc1, PSE and EpCAM that show significant background expression in normal samples, loose its accuracy in tumor cell detection when Ficoll density gradient cell separation methodology is used. In fact, in a separate publication we have demonstrated that using OncoQuick tumor cell enrichment method significantly reduces the background gene expression and therefore increases the sensitivity of tumor cell detection compared to the methodology employing Ficoll density gradient[27].
###end p 56
###begin p 57
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 371 374 371 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam</italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 321 329 <span type="species:ncbi:9606">patients</span>
The mam gene on the other hand, because of its exquisite tissue specificity, did not show any expression in normal PBL. We observed a positive mam signal in 29 (13.5%) patients, which is comparable to studies by Roncella et al [20] and Benoy et al [13] who reported mam positivity in 12% (16/137) and 14% (16/116; M0) of patients, respectively. Other studies have showed mam-based CTC detection ranging from 41% to 62% [24,26,28,29].
###end p 57
###begin p 58
###xml 469 473 469 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 489 492 489 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP</italic>
###xml 601 602 601 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 748 749 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
Positivity thresholds for cancer-associated gene-expression in BM were also set at three standard deviations from the mean in normal BM. Based on this cut-off, 19 patients out of 177 (10.7%) were positive by RT-PCR. All 19 samples were positive for one cancer-associated marker. Additionally, in a subgroup of 83 BM samples analyzed by ICC, five (6%) resulted in a positive staining for cytokeratins. Two out of these five samples were also positive by RT-PCR (one for mam and another for PIP). Reports from other investigators on the incidence of DTC in BM detected by RT-PCR ranged from 12% to 53% [4,12-18] and as high as 80% [6] in metastatic disease. DTC detection by ICC for cytokeratins ranged from 13.2% to 62% (review by Braun et al [1]; [6]). In comparison to these reports the detection of DTC in our study appears to be relatively low. Although our study population contained mainly early stage breast cancer patients (55% in Stage I, 27% in Stage IIA,14% in Stage IIB and 5% in Stage IIIA), we also suspect that the limited volume of bone marrow (average of 3-4 ml) in combination of Ficoll density gradient methodology may not have been sufficient to achieve optimal sensitivity.
###end p 58
###begin p 59
###xml 1066 1070 1066 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 1117 1118 1117 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1191 1194 1191 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam</italic>
###xml 1263 1266 1263 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam</italic>
###xml 1303 1305 1303 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1346 1348 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1407 1411 1407 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
One of our goals in this study was to evaluate whether the expression of any individual gene was associated with poor prognostic indicators. Although the follow-up data for the breast cancer patients in this study is not yet available, we looked at the possible association of the detection of CTC and DTC with traditional clinicopathologic prognostic indicators employing Chi-Square and/or Fisher's exact tests. Among tumor size, histologic grade, ER-, PR-, Her2neu-status, lymph node status and high risk category, we observed a statistically significant association between marker positivity in PBL and histologic grade (grade II-III vs. grade I; p = 0.0083). There were no associations between marker positivity in PBL and pathologic (H&E) and/or molecular (multi-marker RT-PCR) status of axillary lymph nodes. Interestingly, overexpression of the mammaglobin gene alone had also statistically significant association with high grade (p = 0.0315) and showed a trend towards ER-negative tumors (22% vs. 11%) and a high risk category (15% vs. 6%), suggesting that mam gene may be a poor prognostic indicator (Table 3). Although we are not aware of other studies showing similar results on mam, there are reports of statistically significant association between mam-based CTC detection and tumor size [28], clinical stage [24,41], nodal status [42] and distant metastases [42-44] supporting the concept of mam gene being a poor prognostic indicator.
###end p 59
###begin p 60
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 327 328 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP </italic>
###xml 573 577 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 591 594 591 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIP</italic>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 852 856 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
In our study, marker positivity in BM had no statistically significant association with any of the traditional prognostic indicators, however, the results of mam and PIP gene expression in PBL had statistically significant association with the mam and PIP gene expression in BM (p = 2.5E-04 and p = 0.0188, respectively; Table 4). We suggest that this result shows the close connection of PBL and BM compartments and that mam and PIP overexpression is not random but truly indicate the presence of tumor cells. Overall concordance between PBL and BM results were 90.6% for mam and 87.0% for PIP, which is mainly due to the concordance of double negative findings. Concordance for gene-panel was 46.4%. In comparison, Benoy et al demonstrated 68% of concordance between PBL and BM samples using CK19 and 75% concordance between PBL and BM samples using mam gene [13].
###end p 60
###begin p 61
###xml 217 253 217 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">the New England Journal of Medicine </italic>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1034 1037 1034 1037 <sub xmlns:xlink="http://www.w3.org/1999/xlink">PCR</sub>
###xml 1042 1045 1042 1045 <sub xmlns:xlink="http://www.w3.org/1999/xlink">PCR</sub>
###xml 1080 1085 1080 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 1089 1093 1089 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1185 1187 1185 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK</italic>
###xml 1187 1191 1187 1191 <sub xmlns:xlink="http://www.w3.org/1999/xlink">ICC </sub>
###xml 1245 1246 1245 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1262 1267 1262 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
###xml 966 974 <span type="species:ncbi:9606">patients</span>
###xml 1066 1074 <span type="species:ncbi:9606">patients</span>
###xml 1171 1179 <span type="species:ncbi:9606">patients</span>
Clinical relevance of CTC in PBL and DTC in BM can only be studied with sufficient follow-up data. The most comprehensive study has been reported on detection of bone marrow micometastases published by Braun et al in the New England Journal of Medicine [1]. They performed a pooled analysis of a total of nine separate studies involving more than 4,500 breast cancer patients. Braun et al concluded that patients with BM micrometastases had poor overall survival (OS), breast-cancer-specific survival and poor disease-free survival (DFS) and distant-disease-free survival. A prospective, multi-center study by Cristofanilli et al used a new CellSearch System (Veridex) to determine if circulating tumor cells can predict survival in metastatic breast cancer. They tested 177 patients and found that patients with 5 or more tumor cells per 7.5 ml before the therapy and at the first follow-up visit had shorter median progression-free survival and OS compared to the patients with fewer than 5 circulating cells [30]. Benoy et al (CK19PCR, mamPCR) showed worse OS in patients with CK19 and mam expression in BM but not in PBL [13]. Median OS was reported to be shorter in patients with CKICC positive cells in PBL according to Bauernhofer et al [9]. Detection of CK19 positive cells by RT-PCR in PBL in stage I and II was associated with reduced disease-free interval and OS [45].
###end p 61
###begin title 62
Conclusion
###end title 62
###begin p 63
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
The interim results from this prospective clinical trial provides the first report of a statistically significant association between detection of mam mRNA in PBL and high grade breast tumors. Whether this result carries a clinical significance will be seen after the completion of the 5-year follow-up for this study.
###end p 63
###begin title 64
Abbreviations
###end title 64
###begin p 65
###xml 244 248 244 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">mam </italic>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">. PIP </italic>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">. CEA </italic>
###xml 328 334 328 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">. PSE </italic>
###xml 366 371 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CK19 </italic>
###xml 387 394 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">. Muc1 </italic>
###xml 403 411 403 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">. EpCAM </italic>
###xml 464 471 464 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">. Mglo </italic>
###xml 496 498 496 498 <sub xmlns:xlink="http://www.w3.org/1999/xlink">t </sub>
PBL - peripheral blood. BM - bone marrow. CTC - circulating tumor cells. DTC - disseminated tumor cells. SLN - sentinel lymph node. ALN - axillary lymph node. RT-PCR - reverse transcription polymerase chain reaction. ICC - immunocytochemistry. mam - mammaglobin. PIP - prolactin-inducible protein. CEA - carcinoembryonic antigen. PSE - prostate-specific Ets factor. CK19 - cytokeratin 19. Muc1 - mucin 1. EpCAM - epithelial cell adhesion molecule. ErbB2 - Her2/neu. Mglo - beta-2-microglobulin. Ct - cycle threshold.
###end p 65
###begin title 66
Competing interests
###end title 66
###begin p 67
The author(s) declare that they have no competing interests.
###end p 67
###begin title 68
Authors' contributions
###end title 68
###begin p 69
KM contributed to the study design and data interpretation, performed and supervised RNA extraction and real-time RT-PCR, drafted the manuscript. RHM contributed to the study design, performed the statistical analysis, contributed to data interpretation, drafted the manuscript. MBR contributed to the study design and data interpretation, performed RNA extraction and real-time RT-PCR. WEG contributed to the study design and data interpretation, drafted the manuscript. RH interpreted the bone marrow cytology and immunocytochemistry results. DHS provided normal bone marrow specimens. KC coordinated and carried out the protocols for obtaining normal peripheral blood and normal bone marrow specimens. MM contributed to the study design and data interpretation, supervised RNA extraction and real-time RT-PCR, drafted the manuscript. DJC designed the study, contributed to data interpretation, drafted the manuscript and served as a mentor for the entire project. All authors read and approved the final manuscript.
###end p 69
###begin title 70
Pre-publication history
###end title 70
###begin p 71
The pre-publication history for this paper can be accessed here:
###end p 71
###begin p 72

###end p 72
###begin title 73
Acknowledgements
###end title 73
###begin p 74
Source of Support: Department of Defense N00014-99-1-0784
###end p 74
###begin p 75
MIMS Study Group: Marshall M. Urist MD, University of Alabama, Birmingham, AL; Bruce G. Mann MD, Royal Melbourne Hospital, Victoria, Australia; Gerard Doherty MD, Virginia M. Hermann MD, Washington University, St. Louis, MO; Arnold D. Hill MD, St Vincent's University Hospital, Dublin, Ireland; Oleg Eremin MD, Mohamed El-Sheemy MD, Ph.D, Lincoln & Louth County Hospital, Lincoln, England; Richard K. Orr MD, Spartanburg Regional Medical Center, Spartanburg, SC; Alvaro A. Valle MD, University of Tennessee, Chattanooga, TN; Michael A. Henderson MD, St Vincent's Hospital, Victoria, Australia; Lucile Adams-Campell MD, Howard University Cancer Center, Washington, D.C.; Sonia L. Sugg MD, Medical College of Wisconsin, Milwaukee, WI; Eric Frykberg MD, University of Florida Hospital, Jacksonville, FL; Karen Yeh MD, Medical College of Georgia, Augusta, GA; Richard M. Bell MD, Palmetto Health Alliance, Columbia, SC
###end p 75
###begin p 76
We acknowledge the HCC tissue procurement bank and specifically thank Dr. Debra Hazen-Martin and Margaret Romano.
###end p 76
###begin article-title 77
A pooled analysis of bone marrow micrometastasis in breast cancer
###end article-title 77
###begin article-title 78
Bone marrow micrometastases and adjuvant treatment of breast cancer
###end article-title 78
###begin article-title 79
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients?
###end article-title 79
###begin article-title 80
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years
###end article-title 80
###begin article-title 81
###xml 147 155 <span type="species:ncbi:9606">patients</span>
Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients
###end article-title 81
###begin article-title 82
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer
###end article-title 82
###begin article-title 83
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients
###end article-title 83
###begin article-title 84
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity
###end article-title 84
###begin article-title 85
###xml 126 134 <span type="species:ncbi:9606">patients</span>
Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer
###end article-title 85
###begin article-title 86
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: correlation to nodal status and occurrence of metastases
###end article-title 86
###begin article-title 87
Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis
###end article-title 87
###begin article-title 88
Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer
###end article-title 88
###begin article-title 89
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
###end article-title 89
###begin article-title 90
Bone marrow micrometastases detected by RT-PCR for mammaglobin can be an alternative prognostic factor of breast cancer
###end article-title 90
###begin article-title 91
###xml 166 174 <span type="species:ncbi:9606">patients</span>
Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer
###end article-title 91
###begin article-title 92
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients
###end article-title 92
###begin article-title 93
###xml 176 184 <span type="species:ncbi:9606">patients</span>
Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients
###end article-title 93
###begin article-title 94
###xml 192 200 <span type="species:ncbi:9606">patients</span>
Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer
###end article-title 94
###begin article-title 95
###xml 128 136 <span type="species:ncbi:9606">patients</span>
Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR
###end article-title 95
###begin article-title 96
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human mammaglobin mRNA is a reliable molecular marker for detecting occult breast cancer cells in peripheral blood
###end article-title 96
###begin article-title 97
###xml 105 113 <span type="species:ncbi:9606">patients</span>
RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients
###end article-title 97
###begin article-title 98
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse
###end article-title 98
###begin article-title 99
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes
###end article-title 99
###begin article-title 100
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients
###end article-title 100
###begin article-title 101
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
###end article-title 101
###begin article-title 102
Detection of circulating breast cancer cells in peripheral blood by a two-marker reverse transcriptase-polymerase chain reaction assay
###end article-title 102
###begin article-title 103
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology
###end article-title 103
###begin article-title 104
Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA
###end article-title 104
###begin article-title 105
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques
###end article-title 105
###begin article-title 106
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
###end article-title 106
###begin article-title 107
Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel
###end article-title 107
###begin article-title 108
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]
###end article-title 108
###begin article-title 109
Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multi-institutional cohort study
###end article-title 109
###begin article-title 110
Molecular analysis improves sensitivity of breast sentinel lymph node biopsy: results of a multi-institutional prospective cohort study
###end article-title 110
###begin article-title 111
Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR
###end article-title 111
###begin article-title 112
Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes
###end article-title 112
###begin article-title 113
EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
###end article-title 113
###begin article-title 114
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures
###end article-title 114
###begin article-title 115
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer
###end article-title 115
###begin article-title 116
Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
###end article-title 116
###begin article-title 117
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA
###end article-title 117
###begin article-title 118
Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19
###end article-title 118
###begin article-title 119
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Lack of correlation between expression of human mammaglobin mRNA in peripheral blood and known prognostic factors for breast cancer patients
###end article-title 119
###begin article-title 120
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Mammaglobin as a marker for the detection of tumor cells in the peripheral blood of breast cancer patients
###end article-title 120
###begin article-title 121
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance
###end article-title 121

